Skip to main content
BIOTRON LIMITED logo

BIOTRON LIMITED — Investor Relations & Filings

Ticker · BIT ISIN · AU000000BIT4 ASX Professional, scientific and technical activities
Open in API
Filings indexed 765 across all filing types
Latest filing 2016-04-19 Capital/Financing Update
Country AU Australia
Listing ASX BIT

About BIOTRON LIMITED

https://www.biotron.com.au

Biotron Limited is a clinical-stage company focused on the development of novel small molecule antiviral therapeutics. The company utilizes its proprietary ViroPore technology platform to design and develop drugs that target viroporins—a class of proteins found in a wide range of viruses that play critical roles in viral replication and the evasion of host immune responses. Biotron's primary clinical program centers on BIT225, a first-in-class inhibitor targeting the HIV-1 Vpu protein and the Hepatitis C virus p7 protein. The company aims to address unmet medical needs by developing treatments that can potentially eradicate viral reservoirs and improve patient outcomes. In addition to HIV and HCV, Biotron is exploring the application of its antiviral platform against other significant viral pathogens, including SARS-CoV-2, leveraging its expertise in ion channel-targeting chemistry to disrupt the viral life cycle.

Recent filings

Filing Released Lang Actions
$1.5 Million R&D Tax Rebate 2 pages 36.1KB
Capital/Financing Update Classification · 95% confidence The document is a short announcement from Biotron Limited regarding receipt of an R&D Tax Incentive refund for the 2014/15 financial year. It provides details about the refund amount, the program, and how the funds will be used. The document is only 1893 characters long and does not contain any financial statements, detailed financial data, or comprehensive report content. It is an update on a financing-related matter (receipt of a government tax incentive refund) rather than a full financial report or earnings release. Therefore, it fits best under Capital/Financing Update (CAP) as it relates to a financing event impacting the company's cash position.
2016-04-19 English
Letter to Shareholders 3 pages 222.7KB
Regulatory Filings Classification · 95% confidence The document is a shareholder update letter from Biotron Limited dated 12 April 2016. It provides detailed progress information on clinical trials and drug development programs, including results from a Phase 2 study and updates on other viral disease programs. The document is addressed to shareholders and is described as a 'Shareholder Update' in accordance with ASX Listing Rule 3.17. It does not contain financial statements, earnings highlights, or regulatory certifications. It is not a full annual or interim report, nor is it a call transcript or a voting result announcement. The content is informational and intended to update shareholders on company progress and clinical trial results, which aligns with a Regulatory Filing (RNS) as a general regulatory announcement and shareholder communication that does not fit other specific categories. The document length (7704 characters) and content confirm it is not a brief report publication announcement or a formal financial report.
2016-04-11 English
Phase 2 Hepatitis C Trial Success 2 pages 28.8KB
Regulatory Filings Classification · 95% confidence The document is a short announcement (2 pages) dated 17 March 2016 from Biotron Limited to the ASX Limited. It reports positive outcomes from a Phase 2 clinical trial of the drug BIT225 for Hepatitis C. The content focuses on trial results, safety, and future plans, but does not contain detailed financial data, comprehensive analysis, or full report disclosures. It is not a full Annual Report, Interim Report, or Earnings Release. It is also not a regulatory filing or certification. The document is an update on clinical trial progress and results, which fits best under a general regulatory announcement category rather than a financial or governance report. Given the short length and nature of the content, the best classification is Regulatory Filings (RNS), which is the fallback for miscellaneous announcements that do not fit other categories.
2016-03-16 English
Half Yearly Report and Accounts 18 pages 103.2KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'INTERIM FINANCIAL REPORT FOR THE HALF-YEAR ENDED 31 DECEMBER 2015' and includes detailed financial statements such as the Directors' Report, Condensed Interim Statement of Profit or Loss, Statement of Financial Position, Cash Flows, and Notes to the Financial Statements. It also contains an Independent Auditor’s Review Report. The document references the half-year period ended 31 December 2015, indicating it is a comprehensive financial report for a period shorter than a full fiscal year. The presence of substantive financial data and analysis confirms it is an Interim / Quarterly Report rather than a brief announcement or certification. Therefore, the appropriate classification is 'IR' (Interim / Quarterly Report). H1 2016
2016-02-25 English
BIT225 MAY HAVE A BROADER ROLE IN LIMITING HIV-1 INFECTION 2 pages 36.6KB
Regulatory Filings Classification · 95% confidence The document is a short announcement from Biotron Limited dated 18 February 2016, informing about the publication of a scientific manuscript related to their drug BIT225 and its potential role in limiting HIV-1 infection. It mentions that the data has been published in an international scientific journal and provides a link to the manuscript. The document is only 2881 characters long, which is quite short and does not contain any financial data, regulatory filings, or detailed financial reports. It is essentially a news release or announcement about scientific data publication rather than a financial or regulatory report. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or any other financial filing. Given the nature and length, the best fit is Regulatory Filings (RNS) as a general announcement that does not fit other categories.
2016-02-17 English
BIOTRON COMPOUNDS TESTED FOR ACTIVITY AGAINST ZIKA VIRUS 2 pages 24.5KB
Regulatory Filings Classification · 95% confidence The document is a short announcement (only 3790 characters) from Biotron Limited about contracting a laboratory to test antiviral compounds against the Zika virus. It contains no financial data, no detailed financial or operational results, no regulatory certifications, no voting results, no management changes, and no detailed presentations. It is a general corporate update or regulatory announcement about research activities. The document is not a report itself but an announcement of a development. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2016-02-15 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.